| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.vivobio.com | |
| Market Cap | 66.05 Cr. | |
| Enterprise Value(EV) | 126.27 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.59 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 17.14 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 42.18 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 35.69 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 1.24 | Calculated using Price: 44.32 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.49 Cr. | 14,903,520 Shares |
| FaceValue | 10 | |
| About Vivo Bio Tech Ltd. | ||
| Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain. | ||
| 1 Day |
|
+1.22% |
| 1 Week |
|
-0.24% |
| 1 Month |
|
+4.64% |
| 3 Month |
|
+11.56% |
| 6 Month |
|
+32.14% |
| 1 Year |
|
+82.80% |
| 2 Year |
|
+9.15% |
| 5 Year |
|
-10.28% |
| 10 Year |
|
+183.03% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 5.25 | 9.48 | 22.17 | 21.01 | 10.21 | 14.85 | 15.36 | 5.06 | 5.44 | |
| Return on Capital Employed (%) | 4.72 | 5.96 | 12.39 | 15.18 | 9.58 | 13.85 | 18.81 | 9.32 | 11.06 | |
| Return on Assets (%) | 1.14 | 2.09 | 5.17 | 5.64 | 3.92 | 7.58 | 8.02 | 2.18 | 2.16 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 9 | 10 | 13 | 19 | 27 | 33 | 43 | 47 | 52 | 52 | |
| Non Curr. Liab. | 4 | 15 | 22 | 15 | 9 | 9 | 15 | 52 | 46 | 44 | |
| Curr. Liab. | 28 | 20 | 17 | 25 | 19 | 21 | 22 | 23 | 25 | 24 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 122 | 123 | 121 | |
| Non Curr. Assets | 20 | 24 | 32 | 32 | 30 | 35 | 52 | 96 | 91 | 91 | |
| Curr. Assets | 22 | 22 | 20 | 28 | 25 | 27 | 27 | 26 | 32 | 30 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total Assets | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 122 | 123 | 121 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 18 | 29 | 34 | 47 | 56 | 55 | 52 | 51 | 52 | 48 | |
| Other Income | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 19 | 29 | 35 | 47 | 56 | 55 | 52 | 51 | 52 | 49 | |
| Total Expenditure | -15 | -25 | -27 | -36 | -46 | -43 | -34 | -35 | -30 | -26 | |
| PBIDT | 4 | 5 | 8 | 11 | 10 | 13 | 18 | 16 | 22 | 23 | |
| Interest | -1 | 0 | -1 | -2 | -3 | -3 | -4 | -4 | -8 | -8 | |
| Depreciation | -3 | -3 | -4 | -5 | -5 | -5 | -6 | -7 | -9 | -9 | |
| Taxation | 0 | 0 | 0 | -1 | 0 | 0 | -3 | -2 | -2 | -2 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 2 | 3 | 4 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 2 | 3 | 4 | |
| Adjusted EPS | 0 | 1 | 3 | 3 | 2 | 3 | 4 | 2 | 2 | 3 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 3 | 2 | 9 | -6 | 11 | -1 | 9 | 14 | 17 | 15 | |
| Cash Fr. Inv. | -1 | -2 | -7 | -12 | -5 | -4 | -10 | -23 | -51 | -4 | |
| Cash Fr. Finan. | 0 | -1 | 0 | 7 | -3 | 1 | 2 | 9 | 35 | -11 | |
| Net Change | 1 | -1 | 1 | -11 | 3 | -4 | 0 | 0 | 1 | 0 | |
| Cash & Cash Eqvt | 11 | 11 | 12 | 1 | 4 | 1 | 1 | 1 | 2 | 1 |
|
Mon, 22 Apr 2024
Certificate Under Regulation 40(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended March 31 2024 With reference to the above mentioned subject please find enclosed certificate issued by Company Secretary in Practice under Regulation 40(9) read with Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 for the period from April 01 2023 to March 31 2024.This is for your information and records. |
|
Sat, 20 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate we enclosed the information regarding the loss of share certificate(s) received from the shareholder(s) of the company on April 20 2024 aggregating to 30 equity shares. |
|
Sat, 13 Apr 2024
Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Year Ended March 31 2024 In compliance with Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the Certificate signed by the Company Secretary and Compliance Officer of M/s. Vivo Bio Tech Limited and Authorised Signatory from the Registrar and Share Transfer Agent (RTA) of the Company viz. M/s. Aarthi Consultants Private Limited for the period from April 01 2023 to March 31 2024.This is for your information and records |
| Mon, 29 Apr 2024 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
